Lysoway Therapeutics is a clinical-stage biotechnology company dedicated to developing novel therapeutics targeting lysosomal ion channels for the treatment of neurodegenerative diseases. The company's innovative approach focuses on developing highly brain-penetrant small molecule agonists of lysosomal ion channels, particularly TRPML1 (Transient Receptor Potential Cation Channel Subfamily M Member 1) and TMEM175 (Transmembrane Protein 175), to restore autophagy-lysosomal function in age-related neurodegenerative conditions.
Founded in 2020 and headquartered in the United States, Lysoway represents a new generation of biotech companies applying insights from lysosomal biology—historically associated with rare lysosomal storage disorders—to common neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD)[1].
The company's name combines "lysosome" with "pathway," reflecting its fundamental commitment to targeting lysosomal pathways as a therapeutic strategy for neurological disorders. This naming reflects the company's understanding that lysosomal dysfunction is a common thread connecting many neurodegenerative conditions, and that restoring lysosomal function represents a promising therapeutic approach.
The company's approach centers on the well-established link between glucocerebrosidase (GCase) deficiency and Parkinson's disease risk. Mutations in the GBA1 gene, which encodes GCase, represent one of the most significant genetic risk factors for Parkinson's disease, increasing risk by 5-20 fold in carriers of certain variants. This genetic connection has catalyzed substantial interest in developing therapies that can enhance GCase activity or otherwise compensate for lysosomal dysfunction in dopaminergic neurons[2][3].
Lysoway's mission is to develop disease-modifying therapies for neurodegenerative diseases by targeting the autophagy-lysosomal pathway—the cellular cleanup system that becomes progressively dysfunctional with age and is particularly compromised in Alzheimer's and Parkinson's disease.
The company envisions a future where neurodegenerative diseases can be treated not by managing symptoms, but by addressing the underlying cellular dysfunction that drives disease progression. By restoring lysosomal function, Lysoway aims to:
Lysosomes serve as the cellular recycling centers, degrading and recycling proteins, lipids, and organelles through the autophagy-lysosomal pathway. This system becomes progressively less efficient with aging, leading to the accumulation of damaged proteins and organelles that characterize neurodegenerative diseases.
Key findings supporting the lysosomal therapeutic approach include[4][5]:
TRPML1 (also known as MCOLN1) is a lysosomal cation channel that plays a critical role in[6]:
TRPML1 activation promotes:
Activation of TRPML1 has shown promise in preclinical models of Parkinson's disease, particularly in models of alpha-synuclein pathology.
TMEM175 is a lysosomal potassium channel that[7]:
TMEM175 dysfunction has been implicated in both Alzheimer's and Parkinson's disease, making it an attractive therapeutic target. Agonists of TMEM175 aim to enhance lysosomal function and protect against age-related decline.
Lysoway's lead programs utilize small molecule agonists that:
This approach contrasts with:
| Drug | Mechanism | Target | Indication | Stage |
|---|---|---|---|---|
| LY-001 | TRPML1 agonist | MCOLN1 | Parkinson's Disease | Preclinical |
| LY-002 | TMEM175 agonist | TMEM175 | Alzheimer's Disease | Discovery |
| LY-003 | Dual TRPML1/TMEM175 agonist | MCOLN1/TMEM175 | Parkinson's Disease | Discovery |
The lead program targets Parkinson's disease through TRPML1 activation:
Rationale: Parkinson's disease is strongly linked to lysosomal dysfunction. alpha-Synuclein, the protein that forms Lewy bodies in PD brains, is normally cleared through the autophagy-lysosomal pathway. When lysosomal function declines, alpha-synuclein accumulates, forming toxic aggregates that further impair lysosomal function—a vicious cycle that LY-001 aims to break[8][9].
The second program targets Alzheimer's disease:
Rationale: Alzheimer's disease involves accumulation of beta-amyloid plaques and tau tangles, both of which are cleared through the autophagy-lysosomal pathway. TMEM175 dysfunction contributes to lysosomal alkalinization and impaired clearance of these toxic proteins.
Lysoway is also developing compounds that activate both TRPML1 and TMEM175, potentially providing enhanced therapeutic benefit by addressing multiple aspects of lysosomal dysfunction simultaneously.
The lysosomal pathway is critical in neurodegeneration for several interconnected reasons:
The link between GBA1 (glucocerebrosidase) mutations and Parkinson's disease provides compelling evidence for the lysosomal therapeutic approach[2:1][11]:
This genetic evidence strongly supports the hypothesis that lysosomal dysfunction is not just a consequence but a driver of neurodegeneration.
The autophagy-lysosomal pathway is the primary mechanism for cellular protein quality control[12][13]. Key points include:
In neurodegenerative diseases, these pathways are compromised, leading to accumulation of:
The mTOR (mammalian target of rapamycin) pathway tightly regulates lysosomal function[14][13:1]:
Lysoway's approach targets downstream effectors (TRPML1, TMEM175) rather than mTOR directly, potentially providing more selective autophagy enhancement.
Lysoway's initial clinical development focuses on:
The company is developing biomarkers to identify patients most likely to respond:
| Company | Approach | Target | Stage |
|---|---|---|---|
| Sanofi | Enzyme replacement | GCase | Approved (Gaucher), PD preclinical |
| Idorsia | GCase modulator | GCase | Preclinical |
| Takeda | Gene therapy | GCase | Preclinical |
| Lysoway | Ion channel agonist | TRPML1/TMEM175 | Preclinical/Discovery |
| Prevail Therapeutics | Gene therapy | GCase | Phase 1/2 |
| Denali Therapeutics | LRRK2 inhibitor | LRRK2 | Phase 2 |
Lysoway's approach offers several advantages:
| Year | Milestone |
|---|---|
| 2020 | Company founded |
| 2021 | Seed funding round |
| 2022 | Lead program selection |
| 2023 | Series A financing |
| 2024 | Preclinical development |
| 2025-2026 | IND-enabling studies |
Lysoway maintains partnerships with leading academic centers:
Lysoway's leadership combines expertise in:
The company has assembled a team with track records in successful CNS drug development, from discovery through clinical trials.
Lysoway's therapeutic approach interfaces with key biological mechanisms:
See PD Pipeline Companies for a comprehensive list of companies developing Parkinson's disease therapies.
GBA1 mutations and Parkinson's disease: mechanisms and therapeutics. ↩︎ ↩︎
Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. ↩︎
Glucocerebrosidase deficiency promotes alpha-synuclein aggregation in neurons. ↩︎
The interplay between glucocerebrosidase and alpha-synuclein in Parkinson's disease. ↩︎
Gaucher disease glucocerebrosidase and alpha-synuclein form a pathogenic complex in mice. ↩︎
Autophagy enhancers in neurodegenerative disease preclinical models. ↩︎ ↩︎